Literature DB >> 9184700

Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis.

H Xu1, L V Rizzo, P B Silver, R R Caspi.   

Abstract

This study addresses the nature of the pathogenic effector T cell in experimental autoimmune uveoretinitis and the effect of different cytokines on these cells in vitro. Lymph node cells of B10.RIII mice immunized with the uveitogenic peptide 161-180 of interphotoreceptor retinoid binding protein were cultured with the peptide with or without IL-12, IL-4, or anti-IL-4. An antigen-specific T cell line was subsequently derived from these cells. Primary cultures of immune lymph node cells stimulated with the peptide proliferated and produced IL-2 and some IL-4, but no IFN-gamma. The addition of recombinant IL-12 resulted in abundant production of IFN-gamma, which was blocked by the addition of IL-4 and was enhanced by anti-IL-4. Only those cultures that produced IFN-gamma in vitro were uveitogenic in vivo. A long-term uveitogenic T cell line, initially derived in the presence of IL-12, produced IFN-gamma and IL-2, but not IL-4, and was CD4+ (Th1-like). Antigen-specific proliferation and IFN-gamma production of the line were enhanced by exogenous IL-4, TGF-beta, IL-2, IL-6, IL-7, and IL-9 and were inhibited by IL-10 and TNF-alpha. Our results provide support for the hypothesis that the uveitogenic effector T cell has a Th1-like phenotype. Furthermore, the data suggest that the effects of the cytokine milieu on fully differentiated Th1 effectors may differ considerably from their effects on less mature stages of antigen-specific T cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9184700     DOI: 10.1006/cimm.1997.1121

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  31 in total

Review 1.  Immune mechanisms in uveitis.

Authors:  R R Caspi
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Cytokine-based immunointervention in the treatment of autoimmune diseases.

Authors:  L Adorini
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

3.  Characterization of microRNA expression profiling in peripheral blood lymphocytes in rats with experimental autoimmune uveitis.

Authors:  Dadong Guo; Jiao Li; Zhengfeng Liu; Kai Tang; Huixin Song; Hongsheng Bi
Journal:  Inflamm Res       Date:  2015-07-08       Impact factor: 4.575

Review 4.  T cell subsets and their signature cytokines in autoimmune and inflammatory diseases.

Authors:  Itay Raphael; Saisha Nalawade; Todd N Eagar; Thomas G Forsthuber
Journal:  Cytokine       Date:  2014-10-30       Impact factor: 3.861

5.  The effects of atorvastatin in experimental autoimmune uveitis.

Authors:  P B Thomas; T Albini; R K Giri; R F See; M Evans; N A Rao
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

Review 6.  Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?

Authors:  Kenneth G-J Ooi; Grazyna Galatowicz; Virginia L Calder; Susan L Lightman
Journal:  Clin Med Res       Date:  2006-12

Review 7.  Cytokines in posterior uveitis: an update.

Authors:  V K Singh; G Rai
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

8.  IL-9-producing Th9 cells may participate in pathogenesis of Takayasu's arteritis.

Authors:  Li-Li Pan; Juan Du; Na Gao; Hua Liao; Jin Wan; Wei-Ping Ci; Chun Yang; Tian Wang
Journal:  Clin Rheumatol       Date:  2016-09-15       Impact factor: 2.980

9.  Notch signalling suppresses regulatory T-cell function in murine experimental autoimmune uveitis.

Authors:  Hua Rong; Hongjie Shen; Yueli Xu; Hai Yang
Journal:  Immunology       Date:  2016-09-23       Impact factor: 7.397

Review 10.  Regulation, counter-regulation, and immunotherapy of autoimmune responses to immunologically privileged retinal antigens.

Authors:  Rachel R Caspi
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.